Metabolic score for visceral fat as a predictor of new-onset cardiovascular disease in patients with metabolic syndrome: a validation study in two prospective cohorts (UK Biobank and CHARLS).
- 1Department of Cardiology, Suining Central Hospital, No.27 of Dongping North Road, Hedong New District, Suining, Sichuan, China.
- 2Department of Cardiology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
- 3Department of Cardiology, Suining Central Hospital, No.27 of Dongping North Road, Hedong New District, Suining, Sichuan, China. [email protected].
Abstract
Background
Metabolic syndrome (MetS) substantially increases cardiovascular disease (CVD) risk. The metabolism score for visceral fat (METS-VF) is a novel assessment tool that may substitute visceral adipose tissue measurement. This study investigated the association between METS-VF and new-onset CVD in MetS patients.Methods
The data from two prospective cohorts: UK Biobank (UKB) and the China Health and Retirement Longitudinal Study (CHARLS). Multivariate Cox regression and restricted cubic spline (RCS) analyses assessed the association between METS-VF and new-onset CVD. The interaction between METS-VF and the CVD polygenic risk score (PRS) was analyzed in the UKB to assess genetic contributions. Receiver operating characteristic (ROC) curves, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate the discriminative capability of METS-VF for new-onset CVD. Subgroup analyses were performed to confirm the robustness of the results.Results
A total of 101,292 individuals from the UK Biobank and 1,680 individuals from CHARLS were included. The median follow-up periods were 14.6 years in UKB and 5.0 years in CHARLS. High METS-VF was significantly associated with an increased risk of new-onset CVD in both UKB (HR = 1.63, 95% CI: 1.56-1.71) and CHARLS (HR = 2.11, 95% CI: 1.52-2.94) compared with low METS-VF. Individuals with the highest METS-VF and high genetic risk exhibited the highest risk of new-onset CVD (HR = 2.36, 95% CI: 2.14-2.61).Conclusions
METS-VF is a valuable indicator for predicting new-onset CVD in individuals with MetS, providing new insights into the prevention and management of CVD in high-risk populations.Trial registration
Not applicable.
Related
- Pain as a predictor of incident frailty in middle-aged and older adults with metabolic dysfunction-associated steatotic liver disease: a prospective cohort study using machine learning and external validation
- Association of sleep time with all-cause and cardiovascular mortality among individuals with advanced cardiovascular-kidney-metabolic syndrome : A NHANES-based prospective cohort study
- The cardiovascular–liver–metabolic syndemic and mortality and life expectancy: two prospective cohort studies
- Development and validation of a novel metabolic-inflammatory health-related nomogram for predicting in-hospital mortality in older patients with type 2 diabetes mellitus combined with cardiovascular disease
- The cholesterol, high-density lipoprotein, and glucose index and its derivatives related to obesity and inflammation as novel metabolic markers for predicting new-onset cardiovascular-liver-metabolic multimorbidity: A prospective cohort study.
BibTeX
@article{tan2026metabolic,
title = {{Metabolic score for visceral fat as a predictor of new-onset cardiovascular disease in patients with metabolic syndrome: a validation study in two prospective cohorts (UK Biobank and CHARLS).}},
author = {Zhen Tan and Yijun Liu and Lei Liu and Mao Ye and Xinrui Xue and Shuang Li and Xiaoping Li and Hongqiang Ren},
journal = {BMC cardiovascular disorders},
year = {2026},
month = aug,
doi = {10.1186/s12872-026-06299-2},
url = {https://europepmc.org/article/MED/42958482},
note = {CC BY},
}
RIS
TY - JOUR
TI - Metabolic score for visceral fat as a predictor of new-onset cardiovascular disease in patients with metabolic syndrome: a validation study in two prospective cohorts (UK Biobank and CHARLS).
AU - Zhen Tan
AU - Yijun Liu
AU - Lei Liu
AU - Mao Ye
AU - Xinrui Xue
AU - Shuang Li
AU - Xiaoping Li
AU - Hongqiang Ren
PY - 2026
DA - 2026/08/01
JO - BMC cardiovascular disorders
DO - 10.1186/s12872-026-06299-2
UR - https://europepmc.org/article/MED/42958482
AB - Background Metabolic syndrome (MetS) substantially increases cardiovascular disease (CVD) risk. The metabolism score for visceral fat (METS-VF) is a novel assessment tool that may substitute visceral adipose tissue measurement. This study investigated the association between METS-VF and new-onset CVD in MetS patients.Methods The data from two prospective cohorts: UK Biobank (UKB) and the China Health and Retirement Longitudinal Study (CHARLS). Multivariate Cox regression and restricted cubic spline (RCS) analyses assessed the association between METS-VF and new-onset CVD. The interaction between METS-VF and the CVD polygenic risk score (PRS) was analyzed in the UKB to assess genetic contributions. Receiver operating characteristic (ROC) curves, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate the discriminative capability of METS-VF for new-onset CVD. Subgroup analyses were performed to confirm the robustness of the results.Results A total of 101,292 individuals from the UK Biobank and 1,680 individuals from CHARLS were included. The median follow-up periods were 14.6 years in UKB and 5.0 years in CHARLS. High METS-VF was significantly associated with an increased risk of new-onset CVD in both UKB (HR = 1.63, 95% CI: 1.56-1.71) and CHARLS (HR = 2.11, 95% CI: 1.52-2.94) compared with low METS-VF. Individuals with the highest METS-VF and high genetic risk exhibited the highest risk of new-onset CVD (HR = 2.36, 95% CI: 2.14-2.61).Conclusions METS-VF is a valuable indicator for predicting new-onset CVD in individuals with MetS, providing new insights into the prevention and management of CVD in high-risk populations.Trial registration Not applicable.
SN - 1471-2261
ER -